Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Honeybear Biosciences

Request full access

Antibody drug conjugation platform advancing novel cancer therapeutics globally

Taipei, TaiwanFounded 2022Biotech & Life Sciences

About Honeybear Biosciences

HoneyBear Biosciences, Inc, established in 2021, is a Taiwan-based biotech company focused on the global pharmaceutical market. The company specializes in developing new antibody technologies aimed at delivering novel therapeutics to cancer patients. Utilizing its proprietary antibody drug conjugation platform, CoNectar, HoneyBear Biosciences is at the forefront of global drug development. The company's business model revolves around leveraging its powerful antibody engineering platforms to develop and commercialize novel Antibody Drug Conjugates (ADCs) through licensing and co-development partnerships with biotech and pharmaceutical companies. HoneyBear Biosciences aims to improve therapeutic outcomes for cancer patients by creating the next wave of effective anti-cancer medicines. The company serves biotech and pharmaceutical clients, operating in the global pharmaceutical market. Revenue is generated through partnerships and licensing agreements. The management team boasts diverse international experience in chemistry and biological sciences, combining innovative research with rigorous development expertise.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Antibodies, Biotech and Pharma, Antibody-Drug Conjugate, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jul 2026 $20M $80M A*STAR ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Honeybear Biosciences website traffic

Latest recorded traffic for Honeybear Biosciences is 210 monthly website visits, down 46.2% over the last three months.

Latest monthly visits210 3-month web change-46.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Honeybear Biosciences in the Taipei ecosystem

Live from Dealroom

The Honeybear Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • A*STAR
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇹🇼 Taiwan · Taipei HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Honeybear Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Honeybear Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.